ExoTEST is a patented double sandwich ELISA assay for quantitative and qualitative analysis of exosomes. In particular ExoTEST is a successful platform for exosomes quantification and characterization from small amount of human biological fluids or cell media and it may be exploited to identify exosomes released by cancer cells in the plasma and urine of tumor patients in various disease conditions.
ExoTEST consists in ELISA plates pre-coated with proprietary pan-exosome antibodies enabling specific capture of exosomes from different biological samples, including cell culture supernatants and human biological fluids. Quantification and characterization of exosomal proteins is subsequently performed using appropriate detection antibodies against exosome associated antigens that can be for either generic or cell/tissue-specific exosomes. Lyophilized Exosome Standards, charcterized for protein content and particle number (NTA) allow the quantification of unknown sample by a standard calibration curve.
Applications: Exosome capture and quantification from human biofluids and cell culture media. Exosome comprehensive profiling. Pre-clinical research on non-invasive biomarkers for detection and monitoring of a number of pathological conditions (inflammation, cancer, neurodegeneration, etc.).
Advantages: Ready to use, No initial exosome purification required. User friendly and suitable for multiple marker analyses. Available in TEST format (limited to 3 ELISA strips, 24 wells).
Musante, L., Tataruch-Weinert, D., Kerjaschki, D., Henry, M., Meleady, P., & Holthofer, H. (2017). Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment. Journal of Extracellular Vesicles, 6(1), 1267896.
Foster, B. P., Balassa, T., Benen, T. D., Dominovic, M., Elmadjian, G. K., Florova, V., ... & Kyvelidou, C. (2016). Extracellular vesicles in blood, milk and body fluids of the female and male urogenital tract and with special regard to reproduction. Critical reviews in clinical laboratory sciences, (just-accepted), 1-47.
Tas, F., Karabulut, S., Tilgen Yasasever, C., & Duranyildiz, D. (2015). Clinical significance of serum caveolin‐1 levels in melanoma patients. International journal of dermatology.
Zarovni, N., Corrado, A., Guazzi, P., Zocco, D., Lari, E., Radano, G., ... & Chiesi, A. (2015). Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches. Methods.
Miller, I. V., & Grunewald, T. G. (2015). Tumour‐derived exosomes: Tiny envelopes for big stories. Biology of the Cell, 107(9), 287-305.
Hong, C. S., Muller, L., Boyiadzis, M., & Whiteside, T. L. (2014). Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One, 9(8), e103310.
Tetta, C., Ghigo, E., Silengo, L., Deregibus, M. C., & Camussi, G. (2013). Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine, 44(1), 11-19.
Vishnubhatla, I., Corteling, R., Stevanato, L., Hicks, C., & Sinden, J. (2014). The Development of Stem Cell–Derived Exosomes As a Cell-Free Regenerative Medicine. J.Circ. Biomark, 143, 2.
Logozzi, M., De Milito, A., Lugini, L., Borghi, M., Calabrò, L., Spada, M., ... & Fais, S. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. (4), e5219.